OptiBiotix Health PLC GoFigure® distribution agreement for Poland (7617Z)
22 Mayo 2019 - 01:00AM
UK Regulatory
TIDMOPTI
RNS Number : 7617Z
OptiBiotix Health PLC
22 May 2019
OptiBiotix Health plc
("OptiBiotix")
GoFigure(R) distribution agreement for Poland
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high
cholesterol and diabetes, announces it has appointed Extensor as
its exclusive distributor of OptiBiotix's own label GoFigure(R)
consumer weight management products in Poland.
The agreement grants Extensor the exclusive rights to import,
market and distribute OptiBiotix's GoFigure(R) range of meal
replacements, flapjacks and mueslis containing its award winning
SlimBiome(R) technology within the Polish market. This agreement
has been signed accompanied by an initial modest five figure order
and registration of gofigure.pl for online promotion of the
products within the Polish market.
Extensor is a well-known Polish brand that was established over
19 years ago for the creation and promotion of products with the
highest quality and safety levels in the Health and Wellness
sector. The company works with world leaders in the whey protein
industry and in 2002, introduced high-protein supplements to the
Polish market. Extensor has an extensive distribution network
across Poland and is sold through multiple on-line channels,
wholesalers, and retail outlets across shops in Poland.
This agreement is a strategic step to take OptiBiotix's own
label GoFigure(R) products to international markets. This builds
GoFigure(R) brand recognition, enhancing brand value, and creates a
further demand for SlimBiome(R), the functional ingredient within
Gofigure(R) products.
Christina Wood, Sales & Marketing Director commented: "We
are pleased to announce this exclusive distribution deal for the
commercialisation of our GoFigure(R) products in the Polish market.
This is part of a commercial strategy of working across multiple
levels of the value chain (manufacturer, formulator and
distributor) for the supply of white label and own label branded
products. This is the first step in taking OptiBiotix's own label
GoFigure(R) products to international markets. This increases brand
recognition and value in addition to creating a demand for
SlimBiome(R), the functional ingredient within GoFigure(R)
products. This means we are able to derive revenue from both the
sale of our own brand GoFigure(R) products and SlimBiome(R)."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than twenty international food and healthcare
supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of
food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCUAANRKKAVUAR
(END) Dow Jones Newswires
May 22, 2019 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024